Roman Fabbricatore

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

PATHFINDER 2 data build upon bolstered cancer detection rates by the multicancer early detection test found in a previously published PATHFINDER study.

The decision is supported by results from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials.

The use of 68Ga pentixafor complements fluorodeoxyglucose and had no correlation with CXCR4 immunohistochemistry.

Subgroup analyses from the phase 3 CheckMate649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.

Efficacy with etentamig was comparable across prespecified subgroups with relapsed/refractory multiple myeloma, suggesting broad therapeutic benefit.

BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those with disease refractory to prior cBTK and ncBTK inhibition.

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.

Developers have initiated a phase 1 clinical trial evaluating the safety, tolerability, and early antitumor activity of CID-078 in advanced solid tumors.

No new safety signals were observed with liso-cel, with the therapy showing low rates of severe cytokine release syndrome and neurologic events.

More than 80% of patients who were screened for cervical cancer and provided with a self-collection kit did so by utilizing the kit.

The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.

Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

The addition of socazolimab to carboplatin plus etoposide was well tolerated compared with placebo in patients with extensive-stage small cell lung cancer.

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.